DEBATING THE OPERATING CURVES FOR DDU TESTS ON MARKETED INHALERS
|
|
- Stanley Hart
- 5 years ago
- Views:
Transcription
1 DEBATING THE OPERATING CURVES FOR DDU TESTS ON MARKETED INHALERS Industry s problem with the current FDA DDU requirements Presented by Bo Olsson, AstraZeneca R&D Lund on behalf of IPAC-RS DDU Working Group 27 April
2 IPAC-RS developed and submitted PTI test proposal (Nov. 2001) Brief History FDA asked for clarifications, especially for situations with offtarget batch means (Nov 2002) Industry comments indicate DDU specifications too tight FDA Draft CMC Guidances ( ) FDA proposed standards equal to the guidance test as resolution? (Oct 03) Form Working Group under ACPS to resolve remaining issues and finalize test (Jan 2004) IPAC-RS submitted modified procedure (March 2003) FDA asked for theoretical results on other quality standards (April 2003) FDA statisticians discussed additional details (Aug 2003) IPAC-RS submitted requested information and generalized code (June 2003) 2
3 Joint FDA & IPAC-RS Working Group Established in 2004 under FDA Advisory Committee for Pharmaceutical Science (ACPS) Populated by senior representatives from FDA and technical experts from OINDP industry Robert O Neill (Director, Office of Biostatistics, CDER), Chair Moheb Nasr (Director, New Drug Chemistry, CDER) Badrul Chowdhury (Director, Pulmonary Division, CDER) Lawrence Yu (Director, Office of Generic Drugs, CDER) Overall objective: to develop a mutually acceptable, standard DDU specification (test and acceptance criteria) for OINDP, and make a formal recommendation to the ACPS in
4 Consensus Reached to Date Parametric tolerance interval (PTI) approach is an improvement on current DDU test Concept requires refinement and further development to address regulatory requirements It is time to move forward and come to closure Working Group is formed to devote necessary resources and time to resolve issues (through data review and analysis, and development of appropriate statistical procedures) 4
5 Issues where Consensus is Needed Evaluation of simulated performance and actual performance Zero tolerance criterion Statistical details of the test design Applicability to non-normal distributions Better understanding the difference between operating characteristic (OC) curves of draft Guidances and IPAC-RS proposal 5
6 Focus of Today s Presentation FDA is currently not convinced that industry has a problem Show data to demonstrate that Draft Guidance: does not reflect range of OINDP capabilities is overly restrictive compared to non-us public standards does not reflect range of US regulatory practice
7 Data 1. IPAC-RS DDU database (2001) 2. Non-FDA public standards (2004) 3. FDA approved specifications ( ) 7
8 IPAC-RS DDU DATABASE (2001) 80 products*, observations release and real-time stability data * Multiple strengths counted as different products 8
9 Product Status US commercial, approved before % US commercial, approved after % US, phase IIb-application 31% Non-US, commercial 20% Non-US, phase IIb-application 11% Undisclosed 4% US commercial and development products are typically also available on or developed for non-us markets 9
10 Product Types CFC MDI 22% HFA suspension MDI 29% HFA solution MDI 1% Pre-metered DPI 21% Device metered DPI 24% Non-pressurized nasal spray 2% 10
11 observations CFC susp Device met. DPI HFA susp. HFA soln. Pre-met. DPI Product mean Nasal Delivered Dose, %LC Products/batches/tests 11
12 Comparison of Variability grouped by Product Type RSD (%) median RSD CFC HFA HFA Pre-metered Device metered Nasal suspension suspension soln. DPI DPI spray US marketed<1990 US marketed>1990 Non-US marketed US development Non-US development Not disclosed <6% RSD needed to consistently comply with FDA draft specification 12
13 Comparison of Variability grouped by Product Status RSD (%) median RSD US commercial US Development non-us non-us? <1990 >1990 commercial developm. CFC susp HFA susp HFA solution Premetered DPI Device metered DPI Non-pressur. nasal <6% RSD needed to consistently comply with FDA draft specification 13
14 What the Range of Variability Means Practically Majority of products (mostly HFA suspension MDIs and device metered DPIs) would have high failure rate if tested against requirements in Draft Guidance High failure rates are unacceptable from the business perspective Substantially increases cost Stability failures and recalls Process is deemed out of control by the compliance division 14
15 Key Message 1 The DDU requirements in the FDA Guidances are overly restrictive and are not reflective of the range of technological capability of OINDP on the market and in development 15
16 NON-FDA PUBLIC STANDARDS (2004) 16
17 DDU multidose DPI/pMDI Standards in US, Canada, Europe, Australia US CAN EU/AUS Probability to Accept, % Standard Deviation, σ (% of LC) Products in database 22% have RSD<6% 66% have RSD<10% OC curves assuming normal distributed data with batch mean at 100% of label claim and batch standard deviation (σ) made up from equal parts of between-and within-container variation. 17
18 Key Message 2 Public standards for DDU quality other than the FDA Draft Guidances are less stringent, more accurately reflect the range of OINDP capabilities, and represent a better balance between process capability and assuring public safety There appears to be room for alignment of the FDA Draft Guidance standard to other public standards without compromising public safety 18
19 FDA-APPROVED SPECIFICATIONS ( ) COMPARED TO FDA DRAFT GUIDANCE 19
20 IPAC-RS 2003 Survey Requested OC curves for DDU OINDP specifications approved by FDA approved specifications received Frequent exceptions from the draft guidance specification 16 of 24 are to the right of FDA s curve at 90% acceptance and batch mean on target 8 of 24 are to the left (CFC MDIs and nasal suspensions) No chronological pattern observed e.g., more recently approved products are not necessarily all to the right or to the left 20
21 Batch Mean at 100% Label Claim 100 Probability to Accept (%) Batch mean at 100 %LC FDA multidose DPI and MDI Batch standard deviation (% LC) 21
22 Batch Mean 5% off Target 100 Probability to Accept (%) Batch mean at 105 %LC FDA multidose DPI and MDI Batch standard deviation (% LC) 22
23 Batch Mean 10% off Target 100 Probability to Accept (%) Batch mean at 110 %LC FDA multidose DPI and MDI Batch standard deviation (% LC) 23
24 Batch Mean 15% off Target 100 Probability to Accept (%) Batch mean at 115 %LC FDA multidose DPI and MDI Batch standard deviation (% LC) 24
25 What Exceptions? Inner/outer limits Limits on mean Through-container-life testing Life-stage means Sample size Number of actuations in a sample Outlier retesting Other 25
26 Key Message 3 The FDA Draft Guidance requirements do not represent the actual regulatory DDU specifications for many OINDP approved by the FDA since 1990 many OC curves differ substantially from that of the Draft Guidance specification many OINDP will have difficulty meeting the expectations set forth in the Draft Guidance the existence of the range of approved specifications does not negatively impact public health, rather it allows the availability of a range of products and product types to meet the medical need 26
27 EPILOGUE 27
28 Root of the Problem We speculate that Draft Guidance specification is based on historic FDA experience of CFC suspension pmdis Pre-metered DPI Nasal pump sprays Old analytical methodology and sampling plans (excessive priming, beginning only, multiple shots) Now HFA pmdis, multi-dose DPIs and other technologies More discriminating methodology and sampling plans O but same limits 28
29 An in vitro performance standard for DDU is needed such that it: does not reject good batches provides a reasonable target for developers appropriately reflects contemporary formulation and device designs and capabilities of available manufacturing processes avoids frequent exceptions from the public Guidance, coupled with uncertain delays and negotiations during the review and approval process avoids unjustified perception that process is out of compliance Current FDA Draft Guidance s specifications do not fulfil these needs 29
30 Establishing more realistic delivered dose uniformity standards will allow guidance to be both more historically based and forward looking will not change quality of approved products (actual specs approved by FDA) will be more consistent with public standards outside the US will stimulate the development and filing of new and generic products in the US will facilitate and speed up the approval process in the US 30
31 IPAC-RS PTI Test Parametric test simultaneously controls mean and standard deviation no zero tolerance Suitable for all OINDP product types, multidose and single dose Flexible Same consumer protection as FDA draft Guidance Lower producer risk, similar to non-us public standards 31
32 Comparison of OC curves Public standards and IPAC-RS PTI tests US CAN EU/AUS PTI 12/36 PTI 24/72 Probability to Accept, % Standard Deviation, σ (% of LC) 32
33 Conclusion The industry has a problem The 2001 IPAC-RS proposal addresses industry s concerns Joint FDA & IPAC-RS Working Group will work to resolve issues 33
34 Acknowledgments Jeff Blumenstein Mark Broughton Mary Devlin Capizzi David Christopher Claire D Abreu-Hayling Jennifer Gauvin Michael Golden Kristi Griffiths Niels Hartvig Jim Jamieson Paul Kovach Douglas Lee Stefan Leiner Svetlana Lyapustina Bo Olsson David Radspinner Lene Garde Rasmussen Darlene Rosario Dennis Sandell Orin Tempkin Henrik Thoning Keith Truman Ed Warner Steven White Paul Wright Bruce Wyka Jerry Zhang Aradigm AstraZeneca Aventis Boehringer Ingelheim Eli Lilly IPAC-RS Companies GlaxoSmithKline IVAX Kos Nektar Novo Nordisk Novartis Pfizer Schering-Plough 34
COMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationInternational Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
More informationThe Role of EPAG in Standards and Regulatory Guidance Development
The Role of EPAG in Standards and Regulatory Guidance Development Jolyon P. Mitchell on behalf of EPAG Session 4: The Remit, Activities and Achievements of The European Pharmaceutical Aerosols Group 1
More informationBest Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables
Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group PQRI Training Course 12-13 April 2007 Chicago, IL What are leachables
More informationSignificance of Leachables and Extractables to Pharmaceutical Quality
Significance of Leachables and Extractables to Pharmaceutical Quality Gordon Hansen, MS Vice President Analytical Development Ridgefield Boehringer Ingelheim Pharmaceuticals, Inc. Presentation Outline
More informationBrief Overview of the PQRI Recommendations: Challenges and Successes
Brief Overview of the PQRI Recommendations: Challenges and Successes Daniel L. Norwood, MSPH, PhD Distinguished Research Fellow Boehringer Ingelheim Pharmaceuticals, Inc. Available FDA Guidances Container
More informationAssessing Quality of Inhaled Products And Links to Efficacy and Safety
Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationLast updated: July 2011
EFFICIENT DATA ANALYSIS, ABBREVIATED IMPACTOR MEASUREMENTS, AERODYNAMIC PARTICLE SIZE DISTRIBUTIONS: PUBLICATIONS AND PRESENTATIONS BY MEMBERS OF THE IPAC-RS CASCADE IMPACTION WORKING GROUP AND EPAG 2000-2011
More informationImplications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products
Implications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen
More informationEPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010
1 EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010 Overview 2 EPAG, what is it?, background, this project Regulatory
More informationPRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP (EPAG)
PRACTICES OF COATING COLLECTION SURFACES OF CASCADE IMPACTORS: A SURVEY OF MEMBERS OF THE EUROPEAN PHARMACEUTICAL AEROSOL GROUP () J.P. Mitchell on behalf of members of the European Pharmaceutical Aerosol
More informationDemonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products Extended Breakout Session 2: Biomarker Strategies Richard C. Ahrens, M.D. Partha Roy, Ph.D. Dale P. Conner, Pharm.D. Regulatory
More informationOVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA)
OVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA) Terrence P. Tougas on behalf of the IPAC-RS Cascade Impactor Working Group IPAC-RS 2011 Conference 1 CI WG Members 1. Steve Stein 3M 2. Mårten Svenson AstraZeneca
More informationISO Process and Standards Under Development. ISO Principles
Inhalation & Nasal Drugs: The Regulatory Landscape ISO Process and Standards Under Development S.C. Nichols 7 1 ISO Principles ISO standards are developed according to the following principles: Consensus
More informationProcess Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations
Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process
More informationTechnology and Quality of Inhalation Drug Products
Technology and Quality of Inhalation Drug Products Good Development Practices, Specifications, and Analytical Methods for Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Respiratory Drugs 5 6 November
More informationLawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration
Evolving FDA s Approach to Pharmaceutical Quality Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IPAC-RS/University of Florida Orlando Inhalation
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationLessons Learned from Approval of Generic Nasal Products
Lessons Learned from Approval of Generic Nasal Products Julie D. Suman, Ph.D President, Next Breath IPAC-RS/UF Orlando Inhalation Conference: Approaches in International Regulation March 20, 2014 Objectives
More informationSub-components in Nicotine cessation products?
Sub-components in Nicotine cessation products? Mr Arun Sarda, Director of Quality and Regulatory Affairs Member of the HEITKAMP & THUMANN GROUP Regulatory approval of sub-components in nicotine cessation
More informationA Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data
A Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data IPAC-RS/UF Orlando Inhalation Conference March 18-20, 2014 Dennis Sandell, S5 Consulting Contents The data brief
More informationQuality of Nasal and Inhalation Drug Products
Quality of Nasal and Inhalation Drug Products Good Development Practices, Specifications, and Analytical Methods for Inhalation Drug Products (Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI)) and
More informationUnderstanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016
Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,
More information905 UNIFORMITY OF DOSAGE UNITS
Change to read: 905 UNIFORMITY OF DOSAGE UNITS [ NOTE In this chapter, unit and dosage unit are synonymous. ] To ensure the consistency of dosage units, each unit in a batch should have a drug substance
More informationUPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS DDL2017 6-8 December 2017 Presented by Claudia Vincenzi on 7 December 2017 Quality Office EMA An agency of the European
More informationCFCs in inhalers for asthma and COPD
CFCs in inhalers for asthma and COPD What s happening? 2009 United Nations Environment Programme Developed in association with the National Asthma Council Australia Supported by the Multilateral Fund for
More informationOPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER
OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references
More informationA NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING
A NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING Two years ago, Novi Systems Ltd set out to shake up the inhaler automation market. On December 8th, 2015, at the Drug Delivery to the
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
European Medicines Agency Inspections London, 16 February 2005 Doc Ref.: EMEA/CHMP/QWP/49313/2005 corr. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More information040716_ANDI_VENTIS WEBSITE(new) Printout 1. HOME PAGE. Welcome to our world of Dry Powder Inhalers!
1. HOME PAGE Welcome to our world of Dry Powder Inhalers! Andi-Ventis Ltd, established in 2001 is a joint venture between Medochemie Ltd, Cyprus and Miat SpA Italy, founded to carry out the pharmaceutical
More informationVisualization of Study Data to Evaluate UDU Capability. Presented at IFPAC 28 Jan 2015 Thomas Parks, Jeff Hofer, Adam Rauk (Inventive Clinical, LLC)
Visualization of Study Data to Evaluate UDU Capability Presented at IFPAC 28 Jan 2015 Thomas Parks, Jeff Hofer, Adam Rauk (Inventive Clinical, LLC) 1 Motivation Increased expectations to demonstrate acceptable
More informationSterility Assurance and Risk Management: A CDER Microbiologist s Perspective
Sterility Assurance and Risk Management: A CDER Microbiologist s Perspective John W. Metcalfe, Ph.D. Senior Review Microbiologist FDA/CDER/OPQ/OPF/Division of Microbiology Assessment Center for Drug Evaluation
More informationRe: Docket No. FDA D Presenting Risk Information in Prescription Drug and Medical Device Promotion
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org August 25, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationApril 30, By Electronic Mail
April 30, 2018 By Electronic Mail Dr. Scott Gottlieb, Commissioner Office of the Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 CommissionerFDA@fda.hhs.gov
More informationNational Transition Strategy to Replace CFC-based. MDIs with in the Commonwealth of Independent States. Paul Krajnik UNIDO, Montreal Protocol Branch
National Transition Strategy to Replace CFC-based MDIs with HFA-MDIs in the Commonwealth of Independent States Paul Krajnik UNIDO, Montreal Protocol Branch 1 Starting point: total CFC phase-out CFC phase-out
More informationAssessing the role of breathing simulators in OIP testing
As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can
More informationPublic Assessment Report. Scientific discussion. Elisox 50 microgram/actuation, nasal spray, suspension. (mometasone furoate) NL/H/2672/001/DC
Public Assessment Report Scientific discussion Elisox 50 microgram/actuation, nasal spray, suspension (mometasone furoate) NL/H/2672/001/DC Date: 24 September 2014 This module reflects the scientific discussion
More informationMetered Dose Inhaler Technology
Metered Dose Inhaler Technology Edited by Tol S. Purewal and David J. W. Grant Interpharm Press, Inc. Buffalo Grove, Illinois Contents 1. INTRODUCTION 1 T. S. Purewal Definition of the Metered Dose Inhaler
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationHARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION
HARD TWO-PIECE HPMC CAPSULES FOR PHARMACEUTICAL APPLICATIONS IN INHALATION 2 3 QUALICAPS HISTORY Over one hundred years of experience in the manufacturing and filling of hard two-piece capsules Qualicaps
More informationBACKGROUND + GENERAL COMMENTS
Response on behalf of Sobi (Swedish Orphan Biovitrum AB) to the European Commission s Public Consultation on a Commission Notice on the Application of Articles 3, 5 and 7 of Regulation (EC) No. 141/2000
More informationADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY
ADVANCIA : A TRUE PLATFORM & INNOVATIVE SYSTEM OFFERING EFFICIENT NASAL DOSE DELIVERY Millions of people suffering from allergic rhinitis use nasal sprays manufactured by Nemera every day. In this article,
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationDevice Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015
Device Change Management for Inhaled Products Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Topics to be covered Update on ISO/TC 084/WG 15: Guidelines for development of drug products- Quality
More informationCase Study 1: Pharmaceutical Development of EXUBERA
Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human
More informationQualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations. Julie D. Suman, Ph.D. November 14, 2014
Qualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations Julie D. Suman, Ph.D. November 14, 2014 Objectives Container-Closure System Attributes Extractables Regulatory Expectations
More informationGo With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific
Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationGeneric Inhaled Medications
Generic Inhaled Medications Financial Interest Disclosure (over the past 24 months) Irvin Mayers Company Speaker Advisory Research Medimmune Novartis GSK Boehringer Ingelheim CADTH Health Canada Financial
More informationREDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION
REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION In this article, Heli Chauhan, Senior Applications Chemist, and Linda (Lingzhi) Liao, Field Applications Scientist, both of Proveris
More informationEuropean Federation of Statisticians in the Pharmaceutical Industry (EFSPI)
Page 1 of 14 European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) COMMENTS ON DRAFT FDA Guidance for Industry - Non-Inferiority Clinical Trials Rapporteur: Bernhard Huitfeldt (bernhard.huitfeldt@astrazeneca.com)
More informationSingle market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations Brussels,
More informationBioequivalence Requirements: USA and EU
Bioequivalence Requirements: USA and EU Dr. Nicholas Cappuccino Chair, IGPA Science Committee Global Head of Quality, Dr. Reddy s Laboratories Ltd. 15 th Annual IGPA Conference Kyoto, Japan December 6,
More informationCollege of American Pathologists
College of American Pathologists Comments to the Food and Drug Administration on the draft guidance In Vitro Companion Diagnostics Devices October 12, 2011 College of American Pathologists 1350 I Street,
More informationCommunicating the Risk of Nicotine Delivery Products
Communicating the Risk of Nicotine Delivery Products August 10, 2014 ACS National Meeting Jim Solyst June 24, 2014 1 Nicotine Background Key Points The popularity of e-cigarettes has increased the need
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationTitle: Antipsychotic Use in Persons with Dementia CMS ID: ARCO3 NQF #: N/A
Source(s) Pharmacy Quality Alliance (PQA). Technical specifications for PQA approved measures. Springfield (VA): Pharmacy Quality Alliance (PQA); 2015 Jul. 66 p. Measure Domain Clinical Quality Measures:
More informationInstructions for Use neglected opportunity for easy, small wins?
Instructions for Use neglected opportunity for easy, small wins? Julian Dixon IPAC-RS Science Advisor Human Factors Director of Human Factors, Team Consulting Ltd Disclaimer part of this presentation describes
More informationMetered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC
Metered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC William H. Doub, Ph.D. Division of Pharmaceutical Analysis (DPA) US FDA/CDER/OPS/OTR The information presented
More informationNon-inferiority: Issues for today and developments for tomorrow. Kevin Carroll AstraZeneca
Non-inferiority: Issues for today and developments for tomorrow Kevin Carroll AstraZeneca Contents Showing drug effectiveness and requirements for approval Approaches to NI assessment PhRMA CDIG PISC team
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
23 March 2009 EMEA/CHMP/EWP/187653/2009 CPMP/EWP/4151/00 draft 1 Overview of comments received on 'Guideline on the Requirements for clinical documentation for orally inhaled products (OIP) including the
More informationFirst to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction
More informationConsiderations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products
Considerations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products Sven Stegemann Sept 16, 2015 Institute for Process and Particle Engineering, Pharmaceutical Engineering
More informationJuly 7, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
July 7, 2012 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2012-N-0408: Risk Evaluation and Mitigation Strategy Assessments:
More informationGuidance for Industry
Guidance for Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation DRAFT GUIDANCE This document is being distributed for comment
More informationCOPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
More informationAdvancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2
Advancing Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation Day 2 Theresa Mullin, PhD Director, Office of Strategic Programs FDA Center for Drug Evaluation and
More informationBiopharmaceutics of Non-Orally Administrated Drugs
Biopharmaceutics of Non-Orally Administrated Drugs Robert Lionberger, Ph.D. Deputy Director for Science (acting) Office of Generic Drugs, FDA November 21, 2013 AAPS Webinar Opinions expressed in this presentation
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationISSUE BRIEF Conference on Clinical Cancer Research November 2014
ISSUE BRIEF Conference on Clinical Cancer Research November 2014 Introduction Considerations for Summary Review of Supplemental NDA/BLA Submissions in Oncology Rachel Sherman, Principal, Drug and Biological
More informationMeeting the Quality Challenge for Orally Inhaled Drug Products. Review Impact of Emerging EMA/MHRA Guidelines and Standards
IPAC-RS/RDD 2016 SYMPOSIUM Meeting the Quality Challenge for Orally Inhaled Drug Products Review Impact of Emerging EMA/MHRA Guidelines and Standards Joseph Lim (PhD) Senior Pharmaceutical Assessor (MHRA)
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, European Medicines Agency PHARM 689 PHARMACEUTICAL COMMITTEE 21 October 2015
More informationTesting Inhaled Generics
Generic Bioequivalence Testing Inhaled Generics By Mark Copley at Copley Scientific New product-specific FDA guidance and USP monographs support the development of popular inhaled products. This article
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationRDD Europe 2011 Workshop 4 May 2011
RDD Europe 2011 Workshop 4 May 2011 This file represents the slides presented on May 4, 2011 by 3M Drug Delivery Systems at the RDD Europe 2011 Conference in Berlin, Germany. Slides have been modified
More informationChallenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products
Challenges in Meeting International Requirements for Clinical Bioequivalence of Inhaled Drug Products Tushar Shah, M.D. Sr. VP, Global Respiratory Research and Development TEVA Pharmaceuticals 1 Presentation
More informationFILL AMOUNT CONTROL FOR LIQUID AND SEMISOLID DOSAGE FORMS
How to Facilitate First Cycle Approvals Recommendations and Expectations FILL AMOUNT CONTROL FOR LIQUID AND SEMISOLID DOSAGE FORMS Yaodong (Tony) Huang, Ph.D. Quality Assessment Lead (Acting) Branch VIII/Division
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationRe: National Bioengineered Food Disclosure Standard; Proposed Rule; Request for Comments, 83 Fed. Reg (May 4, 2018), Docket No.
VIA ELECTRONIC SUBMISSION July 3, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: National Bioengineered Food Disclosure Standard;
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationReference: FDA Draft Guidance Glass Syringes for Delivering Drug and Biological Products: Technical Information To Supplement ISO Standard
PDA Global Headquarters Bethesda Towers 4350 East West Highway Suite 150 Bethesda, MD 20814 USA Tel: +1 (301) 656-5900 Fax: +1 (301) 986-0296 www.pda.org OFFICERS Chair: Anders Vinther, PhD Genentech Chair-Elect:
More informationBrief history of the development of the Framework on Sharing influenza viruses and access to vaccines and other benefits
Brief history of the development of the Framework on Sharing influenza viruses and access to vaccines and other benefits The Intergovernmental (IGM) Process Since the late 1940's, WHO has coordinated a
More informationIntegration Toxicology/ Chemistry-AET Concept. Daniel L. Norwood, MSPH, PhD Distinguished Research Fellow Boehringer Ingelheim Pharmaceuticals, Inc.
Integration Toxicology/ Chemistry-AET Concept Daniel L. Norwood, MSPH, PhD Distinguished Research Fellow Boehringer Ingelheim Pharmaceuticals, Inc. Threshold Concept Qualification Threshold (QT): 5 µg/day
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More informationUpdate on CDER s Drug Development Tool Qualification Program
Update on CDER s Drug Development Tool Qualification Program ShaAvhree Buckman-Garner, M.D., Ph.D. Director Office of Translational Sciences Center for Drug Evaluation and Research U.S. Food and Drug Administration
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationDraft Guidance for Industry and FDA Staff
Draft Guidance for Industry and FDA Staff Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile DRAFT GUIDANCE This guidance document
More informationJohn Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
More informationWhat Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation
What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects Jolyon P. Mitchell, Ph.D. Trudell Medical International London, Canada IPAC-RS Conference November 2006 1 Context of Presentation This talk
More informationDry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationNAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian
More informationUse of Standards in Substantial Equivalence Determinations
Guidance for Industry and for FDA Staff Use of Standards in Substantial Equivalence Determinations Document issued on: March 12, 2000 U.S. Department Of Health And Human Services Food and Drug Administration
More information